(Q33329539)

25 July 2017

title

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer (English)

1 reference

25 July 2017

1 reference

1 reference

A Buonadonna

5

0 references

author name string

O Pagani

1

1 reference

25 July 2017

C Sessa

2

1 reference

25 July 2017

G Martinelli

3

1 reference

25 July 2017

D Crivellari

4

1 reference

25 July 2017

B Thürlimann

6

1 reference

25 July 2017

D Hess

7

1 reference

25 July 2017

M Borner

8

1 reference

25 July 2017

J Bauer

9

1 reference

25 July 2017

G Zampino

10

1 reference

25 July 2017

M Zimatore

11

1 reference

25 July 2017

R Graffeo

12

1 reference

25 July 2017

A Riva

13

1 reference

25 July 2017

A Goldhirsch

14

1 reference

25 July 2017

publication date

1 May 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

10

1 reference

25 July 2017

issue

5

1 reference

25 July 2017

page(s)

539-545

1 reference

Systemic Therapy of Advanced Breast Cancer

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Drugs ten years later: epirubicin.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

1 reference

7 January 2021

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Management of fever in patients with cancer and treatment-induced neutropenia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Paclitaxel induces significant changes in epidoxorubicin distribution in mice

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026437731354

7 January 2021

Identifiers

DOI

10.1023/A:1026437731354

1 reference

25 July 2017

1 reference